ProMIS Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results

ProMIS Neurosciences (NASDAQ:PMNGet Free Report) announced its earnings results on Monday. The company reported ($0.09) earnings per share for the quarter, reports.

ProMIS Neurosciences Trading Down 9.5 %

Shares of NASDAQ PMN opened at $2.04 on Thursday. The stock’s 50-day moving average is $2.00 and its 200 day moving average is $1.76. The stock has a market cap of $38.62 million, a price-to-earnings ratio of -1.81 and a beta of 0.67. ProMIS Neurosciences has a 1-year low of $0.95 and a 1-year high of $8.95.

Hedge Funds Weigh In On ProMIS Neurosciences

A hedge fund recently bought a new stake in ProMIS Neurosciences stock. Affinity Asset Advisors LLC acquired a new stake in ProMIS Neurosciences, Inc. (NASDAQ:PMNFree Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 265,958 shares of the company’s stock, valued at approximately $527,000. Affinity Asset Advisors LLC owned about 3.10% of ProMIS Neurosciences as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 50.13% of the company’s stock.

About ProMIS Neurosciences

(Get Free Report)

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.

Further Reading

Earnings History for ProMIS Neurosciences (NASDAQ:PMN)

Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with's FREE daily email newsletter.